Sanofi SA (ADR) (SNY), Aegerion Pharmaceuticals, Inc. (AEGR): ISIS Pharmaceuticals, Inc. (ISIS), Big Pharma’s Little Friend

Foolish final thoughts
Enormous revenue potential would exist if the Isis-Roche-developed drugs could even slow the progression of Huntington’s and gain FDA approval. But don’t get too optimistic. Wait until the mid-stage and late-stage trials show some promising data — if that day comes. For now, the Roche deal allows Isis to continue developing drugs and share the risk with big pharma partners at the same time.

The article Isis: Big Pharma’s Little Friend originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.